Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient

被引:12
作者
Colson, Philippe [1 ,2 ]
Bregigeon, Sylvie [3 ]
Tourres, Christian [1 ,2 ]
Solas, Caroline [4 ]
Poizot-Martin, Isabelle [3 ]
Tamalet, Catherine [1 ,2 ]
机构
[1] Aix Marseille Univ, Fac Med & Pharm, URMITE UM CNRS IRD INSERM 63 7278 198 1095, Marseille, France
[2] CHU Timone, IHU Mediterranee Infect, Assistance Publ Hop Marseille, Marseille 05, France
[3] CHU Ste Marguerite Bd Ste Marguerite, Dept Rech Clin, CISIH SUD Serv Hematol, F-13009 Marseille, France
[4] Aix Marseille Univ, AP HM CHU Timone, Lab Pharmacocinet & Toxicol, INSERM CRO2,UMR 911, F-13385 Marseille, France
关键词
Hepatitis C virus; HCV recurrence; Pegylated-interferon alpha plus ribavirin therapy; HIV-HCV coinfection; HCV RNA; PERSISTENCE; CELLS;
D O I
10.1016/j.jcv.2013.05.009
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
It has been demonstrated that sustained virological response (SVR) in patients with chronic hepatitis C indicates resolution of infection. We describe a late hepatitis C virus (HCV) relapse with nearly identical HCV genotype 1a RNA, 14 months after a SVR achievement following a 12-month pegylated-interferon plus ribavirin treatment in a human immunodeficiency virus (HIV) infected patient. This virological relapse occurred concomitantly with interruption of highly active antiretroviral therapy and subsequent increased immunosuppression. HCV retreatment was successful and HCV RNA was undetectable at 50 months of follow-up. This case suggests that late relapse of HCV infection in HIV-positive patients with SVR is possible in case of increased immunodeficiency related to highly active antiretroviral therapy interruption. In such circumstances, a close monitoring of HCV viremia and aminotransferases should be performed. (c) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 21 条
[1]   Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment [J].
Castillo, Inmaculada ;
Rodriguez-Inigo, Elena ;
Lopez-Alcorocho, Juan Manuel ;
Pardo, Margarita ;
Bartolome, Javier ;
Carreno, Vicente .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (10) :1277-1283
[2]   Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].
Chung, RT ;
Andersen, J ;
Volberding, P ;
Robbins, GK ;
Liu, T ;
Sherman, KE ;
Peters, MG ;
Koziel, MJ ;
Bhan, AK ;
Alston, B ;
Colquhoun, D ;
Nevin, T ;
Harb, G ;
van der Horst, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459
[3]   Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient [J].
Colson, Philippe ;
Brouk, Nabil ;
Lembo, Frederique ;
Castellani, Paul ;
Tamalet, Catherine ;
Gerolami, Rene .
HEPATOLOGY, 2008, 47 (02) :766-767
[4]  
Craxì A, 2011, J HEPATOL, V55, P245, DOI 10.1016/j.jhep.2011.02.023
[5]   Relapse of hepatitis C in a pegylated-interferon-α-2b plus ribavirin-treated sustained virological responder [J].
Fujii, Hideki ;
Itoh, Yoshito ;
Ohnishi, Naoki ;
Sakamoto, Masafumi ;
Ohkawara, Tohru ;
Sawa, Yoshihiko ;
Nishida, Koichi ;
Nishimura, Takeshi ;
Yamaguchi, Kanji ;
Yasui, Kohichiroh ;
Minami, Masahito ;
Okanoue, Takeshi ;
Ohkawara, Yasuo ;
Yoshikawa, Toshikazu .
HEPATOLOGY RESEARCH, 2010, 40 (06) :654-660
[6]   Reinfection with hepatitis C virus following sustained virological response in injection drug users [J].
Grebely, Jason ;
Knight, Elizabeth ;
Ngai, Tyler ;
Genoway, Krista A. ;
Raffa, Jesse D. ;
Storms, Michelle ;
Gallagher, Lesley ;
Krajden, Mel ;
Dore, Gregory J. ;
Duncan, Fiona ;
Conway, Brian .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (07) :1281-1284
[7]   Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome [J].
Henry, Mireille ;
Tourres, Christian ;
Colson, Philippe ;
Ravaux, Isabelle ;
Poizot-Martin, Isabelle ;
Tamalet, Catherine .
JOURNAL OF CLINICAL VIROLOGY, 2006, 37 (03) :227-230
[8]   A Crossing in Therapy for Hepatitis C Virus Genotype 2 or 3: Increasing Ribavirin Dose with Shortened Duration or Reducing Ribavirin Dose with Standard Duration [J].
Huang, Chung-Feng ;
Dai, Chia-Yen ;
Huang, Jee-Fu ;
Chunag, Wan-Long ;
Yu, Ming-Lung .
HEPATOLOGY, 2009, 49 (04) :1395-1396
[9]   Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes [J].
Laskus, T ;
Radkowski, M ;
Piasek, A ;
Nowicki, M ;
Horban, A ;
Cianciara, J ;
Rakela, J .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02) :442-448
[10]   Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women [J].
Laskus, Tomasz ;
Operskalski, Eva A. ;
Radkowski, Marek ;
Wilkinson, Jeffrey ;
Mack, Wendy J. ;
deGiacomo, Marina ;
Al-Harthi, Lena ;
Chen, Zhi ;
Xu, Jiaao ;
Kovacs, Andrea .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (01) :124-133